LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

Search

Novo Nordisk A-S

Geschlossen

BrancheGesundheitswesen

56.76 0.71

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

56.36

Max

57.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.5B

27B

Verkäufe

-1.2B

77B

KGV

Branchendurchschnitt

14.483

35.724

EPS

6.53

Dividendenrendite

3.03

Gewinnspanne

34.484

Angestellte

78,387

EBITDA

-2.5B

44B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.85% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.03%

3.09%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

28B

244B

Vorheriger Eröffnungskurs

56.05

Vorheriger Schlusskurs

56.76

Nachrichtenstimmung

By Acuity

95%

5%

359 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Novo Nordisk A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Aug. 2025, 13:52 UTC

Wichtige Markttreiber

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18. Aug. 2025, 09:23 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18. Aug. 2025, 09:23 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6. Aug. 2025, 06:52 UTC

Ergebnisse

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6. Aug. 2025, 06:21 UTC

Ergebnisse

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2. Sept. 2025, 09:14 UTC

Heiße Aktien

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21. Aug. 2025, 08:49 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18. Aug. 2025, 09:23 UTC

Heiße Aktien

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8. Aug. 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. Aug. 2025, 11:32 UTC

Ergebnisse

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. Aug. 2025, 11:03 UTC

Ergebnisse

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. Aug. 2025, 10:41 UTC

Ergebnisse

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6. Aug. 2025, 20:34 UTC

Ergebnisse

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6. Aug. 2025, 08:45 UTC

Ergebnisse

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6. Aug. 2025, 07:19 UTC

Market Talk
Ergebnisse

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6. Aug. 2025, 05:50 UTC

Ergebnisse

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6. Aug. 2025, 05:48 UTC

Ergebnisse

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6. Aug. 2025, 05:46 UTC

Ergebnisse

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6. Aug. 2025, 05:38 UTC

Ergebnisse

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6. Aug. 2025, 05:37 UTC

Ergebnisse

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6. Aug. 2025, 05:36 UTC

Ergebnisse

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6. Aug. 2025, 05:35 UTC

Ergebnisse

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6. Aug. 2025, 05:34 UTC

Ergebnisse

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6. Aug. 2025, 05:31 UTC

Ergebnisse

Novo Nordisk 2Q Net Pft DKK26.5B

6. Aug. 2025, 05:31 UTC

Ergebnisse

Novo Nordisk 2Q Oper Pft DKK33.45B

6. Aug. 2025, 05:31 UTC

Ergebnisse

Novo Nordisk 2Q Sales DKK76.86B

5. Aug. 2025, 21:58 UTC

Ergebnisse

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5. Aug. 2025, 17:26 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5. Aug. 2025, 15:15 UTC

Ergebnisse

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5. Aug. 2025, 10:07 UTC

Market Talk

Novo Nordisk's Facing Challenging Times -- Market Talk

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

19.85% Vorteil

12-Monats-Prognose

Durchschnitt 67.57 USD  19.85%

Hoch 90 USD

Tief 50 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

2

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

62.63 / 69.23Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

359 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.